( NASDAQ-NMS:JAZZ )

News from Jazz Pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 18, 2017, 07:00 ET Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced an offering by Jazz Investments I Limited, its wholly-owned...


Aug 17, 2017, 16:07 ET Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), of...


Aug 08, 2017, 16:05 ET Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results

Received FDA Approval of Vyxeos for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with...


Aug 03, 2017, 10:15 ET Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, August 7, 2017 at 4:30 p.m. EDT/9:30 p.m....


Jul 26, 2017, 16:05 ET Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a license agreement with XL-protein GmbH ("XLp") for the rights to...


Jul 24, 2017, 16:05 ET Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 second quarter financial results on Tuesday, August 8, 2017,...


Jun 06, 2017, 17:05 ET Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented positive efficacy results from its global multicenter studies (TONES 3 and TONES 4) of...


Jun 06, 2017, 17:00 ET Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented the positive efficacy results from its global multicenter study of JZP-110 in adult...


May 31, 2017, 16:05 ET Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with...


May 24, 2017, 16:07 ET Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to discuss data to be presented on JZP-110 and Xyrem®...


May 24, 2017, 16:05 ET Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that twelve abstracts supporting the company's sleep medicine portfolio, including...


May 16, 2017, 16:05 ET Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


May 09, 2017, 16:05 ET Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results

Total Revenues Increased 12% to $376 Million Settled Xyrem Patent Litigation with First ANDA Filer Completed Rolling NDA Submission for Vyxeos...


Apr 26, 2017, 16:05 ET Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy results from the global multicenter study of JZP-110 in adult patients...


Apr 25, 2017, 16:05 ET Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 first quarter financial results on Tuesday, May 9, 2017, after...


Apr 05, 2017, 16:30 ET Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that certain of its subsidiaries have entered into agreements with Hikma Pharmaceuticals...


Apr 03, 2017, 09:05 ET Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion on March 31, 2017 of a rolling submission of a New Drug Application (NDA) to...


Mar 30, 2017, 02:00 ET Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into license agreements with Nippon Shinyaku, Co., Ltd. for Defitelio®...


Mar 20, 2017, 09:00 ET Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy results from two global multicenter studies in adult patients with...


Mar 15, 2017, 16:05 ET Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical study evaluating JZP-258, an...


Mar 01, 2017, 16:05 ET Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


Feb 28, 2017, 16:05 ET Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2016 and provided financial...


Feb 14, 2017, 16:05 ET Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2016 fourth quarter and full year financial results on Tuesday,...


Feb 08, 2017, 16:05 ET Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a...